Back to top
more

CRISPR Therapeutics (CRSP)

(Delayed Data from NSDQ)

$79.41 USD

79.41
1,170,568

+1.02 (1.30%)

Updated Dec 8, 2021 04:00 PM ET

After-Market: $79.37 -0.04 (-0.05%) 5:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.42%
2Buy19.05%
3Hold10.68%
4Sell6.41%
5Strong Sell3.08%
S&P50011.42%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (154 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

CRISPR Therapeutics AG (CRSP) Down 17.4% Since Last Earnings Report: Can It Rebound?

CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Vertex (VRTX) Up on Kidney Disease Drug's Success in Phase II

Vertex's (VRTX) APOL1 inhibitor, VX-147, led to a significant reduction in protein in urine in a phase II study in APOL1-mediated FSGS, a severe kidney disorder.

CRISPR's (CRSP) CAR-T Cell Therapy Gets FDA's RMAT Designation

The FDA grants a Regenerative Medicine Advanced Therapy designation to CRISPR Therapeutics' (CRSP) CTX110 targeting CD19+ B-cell malignancies.

CRISPR (CRSP) to Begin Clinical Study on Diabetes Therapy Drug

CRISPR Therapeutics (CRSP) receives clearance from Health Canada to initiate clinical studies for VCTX210, its investigational therapy for the treatment of type 1 diabetes.

CRISPR Therapeutics (CRSP) Q3 Earnings Beat, Revenues Lag

CRISPR Therapeutics (CRSP) reports narrower-than-expected Q3 loss. Yet, revenues miss estimates for the third quarter of 2021.

CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 1.18% and -78.57%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Vertex (VRTX) Beats on Q3 Earnings & Sales, Raises '21 View

Vertex Pharmaceuticals' (VRTX) earnings and sales beat estimates for the third quarter of 2021. The company raises its product revenue guidance for the year.

CRISPR (CRSP) to Report Q3 Earnings: What's in the Cards?

On CRISPR Therapeutics' (CRSP) Q3 earnings call, investor focus will likely be on updates on the company's pipeline candidates, especially its lead candidate CTX001.

Intellia's (NTLA) CRISPR Therapy Gets FDA's Orphan Drug Tag

Intellia's (NTLA) investigational gene-editing therapy, NTLA-2001, gets Orphan Drug tag from the FDA for ATTR amyloidosis.

Earnings Preview: CRISPR Therapeutics AG (CRSP) Q3 Earnings Expected to Decline

CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vertex's (VRTX) Early Type I Diabetes Study Data Promising

Vertex's (VRTX) single infusion drug candidate, VX-880, for type I diabetes shows restoration of insulin production and robust improvements in multiple measures in a phase I/II study

The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics

The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics

Indrajit Bandyopadhyay headshot

4 Biotechs to Watch Amid Rising Prominence of Gene Therapies

Here we discuss four biotech companies, CRSP, EDIT, SRPT and BEAM, that have the potential to gain from their promising gene therapy pipeline candidates.

Editas (EDIT) Focuses on Developing Gene Drug for Eye Disease

Editas (EDIT) progresses well with the development of its lead candidate, EDIT-101, to treat LCA10, a rare genetic illness that causes blindness. Dependence on partners for revenues is a concern.

Madeleine Johnson headshot

Why CRISPR Therapeutics (CRSP) Stock is Falling Today

Shares of leading gene editing company CRISPR Therapeutics (CRSP) are sliding on Friday. What's behind the slump?

CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $111.93, marking a +1.57% move from the previous day.

Editas (EDIT) Down on Initial Data From Eye Disease Study

Editas (EDIT) posts initial data from the phase I/II BRILLIANCE study evaluating EDIT-101 for treating Leber congenital amaurosis 10, an inherited form of blindness.

CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should Know

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $117.81, moving +0.48% from the previous trading session.

Why CRISPR Therapeutics AG (CRSP) is a Top Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.

5 Reasons to Buy Vertex Pharmaceuticals (VRTX) Stock Now

New reimbursement agreements in ex-U.S. markets and label expansions to younger age groups should drive sales of Vertex's (VRTX) cystic fibrosis drug, Trikafta sales higher.

CRISPR Therapeutics AG (CRSP) Stock Moves -0.59%: What You Should Know

CRISPR Therapeutics AG (CRSP) closed at $120.74 in the latest trading session, marking a -0.59% move from the prior day.

CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $127.07, marking a +0.56% move from the previous day.

Vertex (VRTX) Inks New Deal for CRISPR Gene-Editing Rights

Vertex (VRTX) collaboration with Arbor will support discovery & development of new treatment options for serious diseases using the latter's CRISPR technology.

Earnings Growth & Price Strength Make CRISPR Therapeutics AG (CRSP) a Stock to Watch

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.

Editas (EDIT) Up More Than 70% in Past 3 Months: Here's Why

Editas' (EDIT) lead candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. The company is also developing EDIT-301 for treating hematologic diseases.